NCT06427447RecruitingPhase 3
Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
Adjuvant Chemoradiotherapy Versus Chemotherapy for Post-operative Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 4 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In this trial, we aim to compare the outcomes of adjuvant chemoradiotherapy with chemotherapy for patients with resected pancreatic cancer who are at high risk of disease progressions.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 770 (estimated)
- First submitted
- 19 May 2024
- Start date
- 6 Aug 2024
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- Changhai Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT06427447
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 770
- From 6 Aug 2024 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of cancer treatment after surgical resection
- History of other cancers within 5 years
- Disease progression, including local pprogression or metastasis, confirmed by imaging examinations
- Active inflammatory bowel disease
- Gastrointestinal bleeding or perforation within 6 months
- Infections requiring antibiotics
- Heart or respirotory insufficiency
Other
- ECOG ≥2 points
- Significant abnormality in blood routine test, liver and kidney function test and coagulation test
- Pregnant women or breastfeeding women
Who the study is looking for
- Aged 18-75 years
- Pathologically confirmed pancreatic ductal adenocarcinoma
- Pathologically confirmed lymph node metastasis, R1 or R2 resection or lymphovascular invasion (one of the risk factors)
- No history of cancer treatment after surgical resection
- No disease progression confirmed by imaging examinations
- ECOG 0 to1 point
- No abnormality in blood routine test, liver and kidney function test and coagulation test (White blood cell count ≥4.0×10\^9/L, neutrophil count ≥2.0×10\^9, hemoglobin level ≥100g/L, platelet count ≥100×10\^9/L, ALT and AST level \< 2.5 times the upper limit of normal, total bilirubin and creatinine level within the normal, international normalized ratio \<2)
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Huojun Zhang Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.